Anti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas)
Drug Alias NameRFB4-N97AIMTOX 22 N97AIMTOX-22
ClassificationBiologics > Protein drugs > Toxin
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUcl Medical SchoolUniversity of Texas Southwestern Medical CenterGalileo Research +[5] 
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of Texas Southwestern Medical CenterNational Institutes Of HealthCancer Research Technology +[6] 
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A